Amylyx Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AMLX Nasdaq 2830 amylyx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf. - Mar 10th, 2026 7:52 pm
Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... - Mar 4th, 2026 6:02 pm
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Reduced Losses And Late Stage Pipeline Progress - Mar 4th, 2026 4:08 am
Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout - Mar 4th, 2026 1:57 am
Amylyx Refocuses On Avexatide As LUCIDITY Milestone Raises Stakes - Mar 3rd, 2026 10:10 pm
Amylyx Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Mar 3rd, 2026 10:32 am
Amylyx Pharmaceuticals Q4 Earnings Call Highlights - Mar 3rd, 2026 9:18 am
Amylyx (AMLX) Q4 2025 Earnings Call Transcript - Mar 3rd, 2026 7:40 am
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - Mar 3rd, 2026 5:00 am
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences - Feb 26th, 2026 7:00 am
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - Feb 25th, 2026 1:26 pm
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - Feb 25th, 2026 1:19 pm
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst - Feb 25th, 2026 1:11 pm
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 - Feb 24th, 2026 7:00 am
Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - Feb 19th, 2026 1:30 am
Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million - Jan 31st, 2026 10:09 pm
How Investors May Respond To Gubra (CPSE:GUBRA) Securing Amylyx GLP-1 Milestones And Royalty Upside - Jan 22nd, 2026 1:12 pm
Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders - Jan 19th, 2026 6:01 am
Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage - Jan 11th, 2026 11:09 am
Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases - Jan 10th, 2026 12:57 pm